Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit ...

AI-leveraged drug development has become an $18 billion industry, but companies in the sector are experiencing some hardships ...

Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer.Strong ...

Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026.

Hong Kong, November 9, 2020] Deqi Pharmaceutical Co., Ltd. (" Deqi Pharmaceutical " or " the Company ", together with its subsidiaries, collectively referred to as " the Group "; Stock Code: 6996.HK ) ...

Novonesis and Novo Nordisk have formed a research partnership to study how the gut microbiome can support metabolic health and help prevent obesi ...

EngagesFormerFDADirectorof DivisionofCardiologyandNephrology,Norman Stockbridge, M.D., Ph.D., to Advise on Walden’s Clinical Pipeline in Rare Kidney Diseases ...

Dr. Trieu’s prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among others Oncotelic’s robust portfolio and ...

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily ...

Copyright © 2025 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service ...

Abstract: Current memristive circuits for biological decision-making only consider simple situations and do not take into account how the organisms themselves learn these behaviors. In this article, a ...